Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
TRANSCEND-T2D: Eli Lilly's parallel Phase 3 program evaluating retatrutide in type 2 diabetes
That means: the current evidence comes from clinical trials and sponsor announcements
however, trim-and-fill imputed no missing studies, and the pooled estimate was unchanged (SMD 1.201, 95% CI 2.115 to 0.287)
As our understanding of GLP-1 receptor agonists grows, these medications may play an even larger role in treating a wide range of metabolic and obesity-related health issues
Mindful and circadian-aligned eating
DOI: 10.1530/EC-18-0514 Camacho EM, Huhtaniemi IT, ONeill TW, et al
US$ 29.45
US$ 28.85
US$ 22.35
US$ 25.69
